Answers are grounded in this paper and cite their sources.
Added to standard chemotherapy, rituximab improved survival in patients with non-Hodgkin's lymphoma; added to fludarabine-based regimens, it improved response and survival in patients with chronic B-cell lymphocytic leukemia.
No takes yet. Share an insight, caveat, or question.
Jill Atmar (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: